BioSig Technologies, Inc. (BSGM)

Beyond the Status Quo

As physician advocates, we develop technology that provides greater clarity and opens doors to ingenious treatment solutions for the most challenging arrhythmias. We collaborate with physicians, experts, and healthcare leaders to align on the advancements that can be realized in the field of electrophysiology.

We are driven by a commitment to provide innovative solutions that elevate the standard of care. Our engineers are constantly in search of what’s possible in signal acquisition and the field of electrophysiology, driving the evolution of our technology for the physicians we serve.

An Innovation in One of the Most Critical Areas of Electrophysiology

The PURE EP™ Platform applies a unique combination of hardware and software to accurately capture intracardiac signals with unprecedented clarity and precision. By viewing pure signals that are absent of saturation, interference, or noise from other medical equipment, physicians can respond to even the most complex cardiac arrhythmias with insight-based, highly targeted cardiac ablation procedures.

Discover the PURE EP™ Platform

MEETING THE NEED TO IMPROVE ARRHYTHMIA TREATMENT

"If we improve the fidelity of our [signal] recordings, we can potentially improve the efficiency and safety of our procedures. In that respect, the PURE EP™ System is really a breath of fresh air in this field."

- Hicham El Masry, M.D. (Mayo Clinic, Arizona)
Leveraging EGMs to Improve Efficacy, Safety of Ablation Kansas City Heart Rhythm Symposium (KCHRS) 2022

Discover BioSig

BioSig is on the leading edge of digital signal processing in healthcare. Join us on the front lines to unlock the future of cardiac treatment and help transform healthcare.

Company

BioSig is an advanced signal processing company delivering unmatched accuracy and precision to intracardiac signal visualization, and enhancing the treatment of arrhythmias.

Learn more about BioSig

Leadership

By uniting the diverse talents and collective experiences of industry experts, we are determined to break down barriers and go beyond our comfort zone in pursuit of unconventional solutions that advance medical technology and make a lasting impact.

Insights

With the superior, real-time visualization of arrhythmias, PURE EP™ is paving the way for personalized patient care and breakthrough innovations in the field of electrophysiology. View the latest cases, presentations, and papers.

News & Stories

Streamex (BSGM) to Participate in the 5th Annual Needham Virtual Crypto 1x1 Conference on September 4th

August 28, 2025

LOS ANGELES, CA & VANCOUVER, BC , Aug. 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ('BioSig' or the 'Company'), which recently merged with Streamex Exchange Corporation ('Streamex') (NASDAQ: BSGM), a gold tokenization infrastructure company building the foundation for on-chain gold markets, today announced that it will participate in the 5th annual Needham Virtual Crypto 1x1 Conference on September 4th, 2025. BioSig and Streamex CEO, Henry McPhie and CIO, Mitch Williams will host one on one meetings with institutional investors at the conference.

BioSig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering

August 15, 2025

Offering Structured to Accelerate Streamex's Operational Build-Out, Strategically Allocated with No Warrants

BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering

August 13, 2025

Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ('BioSig' or the 'Company'), which recently merged with Streamex Exchange Corporation ('Streamex') (NASDAQ: BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes.

Delivering Superior Signal Clarity